Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Pfizer Inc. stock logo
PFE
Pfizer
$23.36
+1.0%
$22.95
$20.92
$31.54
$132.81B0.5740.96 million shs30.40 million shs
Redfin Co. stock logo
RDFN
Redfin
$9.96
-0.2%
$9.41
$5.49
$15.29
$1.28B2.56.58 million shs4.42 million shs
20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Pfizer Inc. stock logo
PFE
Pfizer
+1.10%-0.43%+2.56%-12.53%-20.95%
Redfin Co. stock logo
RDFN
Redfin
-0.20%-0.50%+11.04%+71.13%+42.49%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Pfizer Inc. stock logo
PFE
Pfizer
4.9902 of 5 stars
3.35.04.24.32.71.73.1
Redfin Co. stock logo
RDFN
Redfin
2.8613 of 5 stars
2.12.00.03.21.72.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Pfizer Inc. stock logo
PFE
Pfizer
2.53
Moderate Buy$29.1724.86% Upside
Redfin Co. stock logo
RDFN
Redfin
2.14
Hold$10.454.92% Upside

Current Analyst Ratings Breakdown

Latest RDFN and PFE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/19/2025
Redfin Co. stock logo
RDFN
Redfin
Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMixed ➝ Mixed
5/8/2025
Redfin Co. stock logo
RDFN
Redfin
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$7.30 ➝ $9.20
5/8/2025
Redfin Co. stock logo
RDFN
Redfin
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$12.50 ➝ $11.00
4/30/2025
Pfizer Inc. stock logo
PFE
Pfizer
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$24.00 ➝ $25.00
4/22/2025
Pfizer Inc. stock logo
PFE
Pfizer
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight ➝ Neutral$24.00
4/15/2025
Redfin Co. stock logo
RDFN
Redfin
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSector Perform ➝ Sector Perform$8.00 ➝ $12.50
4/8/2025
Pfizer Inc. stock logo
PFE
Pfizer
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$28.00 ➝ $24.00
4/8/2025
Pfizer Inc. stock logo
PFE
Pfizer
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral$32.00 ➝ $25.00
3/27/2025
Pfizer Inc. stock logo
PFE
Pfizer
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral
3/24/2025
Redfin Co. stock logo
RDFN
Redfin
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$7.00 ➝ $12.50
3/18/2025
Pfizer Inc. stock logo
PFE
Pfizer
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
(Data available from 6/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Pfizer Inc. stock logo
PFE
Pfizer
$62.46B2.13$3.66 per share6.38$15.81 per share1.48
Redfin Co. stock logo
RDFN
Redfin
$1.04B1.23N/AN/A$0.02 per share498.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Pfizer Inc. stock logo
PFE
Pfizer
$8.03B$1.3816.577.710.6412.62%19.47%8.09%7/29/2025 (Estimated)
Redfin Co. stock logo
RDFN
Redfin
-$130.03M-$1.53N/AN/AN/A-14.88%N/A-13.28%8/5/2025 (Estimated)

Latest RDFN and PFE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/6/2025Q1 2025
Redfin Co. stock logo
RDFN
Redfin
-$0.69-$0.73-$0.04-$0.73$220.89 million$221.03 million
4/29/2025Q1 2025
Pfizer Inc. stock logo
PFE
Pfizer
$0.67$0.92+$0.25$0.52$14.43 billion$13.72 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Pfizer Inc. stock logo
PFE
Pfizer
$1.727.36%N/A124.64%16 Years
Redfin Co. stock logo
RDFN
Redfin
N/AN/AN/AN/AN/A

Latest RDFN and PFE Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/23/2025
Pfizer Inc. stock logo
PFE
Pfizer
quarterly$0.437.69%5/9/20255/9/20256/13/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Pfizer Inc. stock logo
PFE
Pfizer
0.63
1.00
0.73
Redfin Co. stock logo
RDFN
Redfin
N/A
1.50
1.50

Institutional Ownership

CompanyInstitutional Ownership
Pfizer Inc. stock logo
PFE
Pfizer
68.36%
Redfin Co. stock logo
RDFN
Redfin
61.07%

Insider Ownership

CompanyInsider Ownership
Pfizer Inc. stock logo
PFE
Pfizer
0.06%
Redfin Co. stock logo
RDFN
Redfin
4.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Pfizer Inc. stock logo
PFE
Pfizer
83,0005.69 billion5.66 billionOptionable
Redfin Co. stock logo
RDFN
Redfin
5,570128.03 million118.53 millionOptionable

Recent News About These Companies

Senators scrutinize Rocket's Redfin, Mr. Cooper deals
Redfin-Rocket Deal Clears Hurdle After Judge Denies Vote Delay
Vote on Redfin-Rocket deal goes ahead as planned
Roadblock for Redfin shareholder vote on Rocket merger removed
Rocket's acquisition of Redfin OK'd by shareholders
Sellers Outnumber Buyers in the Housing Market

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Pfizer stock logo

Pfizer NYSE:PFE

$23.36 +0.24 (+1.04%)
Closing price 06/6/2025 03:59 PM Eastern
Extended Trading
$23.39 +0.03 (+0.13%)
As of 06/6/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Redfin stock logo

Redfin NASDAQ:RDFN

$9.96 -0.02 (-0.20%)
Closing price 06/6/2025 04:00 PM Eastern
Extended Trading
$9.94 -0.02 (-0.20%)
As of 06/6/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Redfin Corporation operates as a residential real estate brokerage company in the United States and Canada. The company operates an online real estate marketplace and provides real estate services, including assisting individuals in the purchase or sell of home. It also provides title and settlement services; and originates and sells mortgages. In addition, the company uses digital platforms to connect consumers with rental properties. The company was formerly known as Appliance Computing Inc. and changed its name to Redfin Corporation in May 2006. Redfin Corporation was incorporated in 2002 and is headquartered in Seattle, Washington.